{"id":415,"date":"2023-08-25T13:57:15","date_gmt":"2023-08-25T05:57:15","guid":{"rendered":"https:\/\/consulting-hmk.com\/?p=415"},"modified":"2024-01-18T09:56:47","modified_gmt":"2024-01-18T01:56:47","slug":"retagliptin-phosphate-tablets-approved-for-marketing-by-china-nmpa","status":"publish","type":"post","link":"https:\/\/www.consulting-hmk.com\/pt\/retagliptin-phosphate-tablets-approved-for-marketing-by-china-nmpa\/","title":{"rendered":"Comprimidos de fosfato de retagliptina aprovados para comercializa\u00e7\u00e3o pela NMPA da China"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0 \u00a0 \u00a0 Recentemente, o medicamento inovador de categoria 1 Retagliptin Phosphate Tablets (nome comercial chin\u00eas: \u745e\u6cfd\u5510) da Jiangsu Hengrui Pharmaceuticals Co., Ltd. foi aprovado pela China NMPA. \u00c9 indicado para melhorar o controlo da glicose no sangue para pacientes adultos com diabetes tipo 2.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-395 aligncenter\" title=\"Comprimidos de fosfato de retagliptina aprovados para comercializa\u00e7\u00e3o pela NMPA da China\" src=\"https:\/\/consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-300x168.jpg\" alt=\"Comprimidos de fosfato de retagliptina aprovados para comercializa\u00e7\u00e3o pela NMPA da China\" width=\"568\" height=\"318\" srcset=\"https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-300x168.jpg 300w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-1024x574.jpg 1024w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-768x430.jpg 768w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-1536x861.jpg 1536w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-2048x1148.jpg 2048w\" sizes=\"(max-width: 568px) 100vw, 568px\" \/><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">O Fosfato de Retagliptina \u00e9 um inibidor da dipeptidil peptidase 4 (DPP-4) que inibe a DPP-4 para hidrolisar a hormona incretina, aumentando assim a concentra\u00e7\u00e3o plasm\u00e1tica do p\u00e9ptido-1 semelhante ao glucagon ativo (GLP-1) e do p\u00e9ptido semelhante \u00e0 insulina dependente da glicose (GIP). Aumenta a liberta\u00e7\u00e3o de insulina de forma dependente da glucose e diminui o glucagon para reduzir a glucose no sangue. A comercializa\u00e7\u00e3o deste medicamento proporciona novas op\u00e7\u00f5es de tratamento para os doentes adultos com diabetes de tipo 2.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Recentemente, o medicamento inovador de categoria 1 Retagliptin Phosphate Tablets da Jiangsu Hengrui Pharmaceuticals Co., Ltd. foi aprovado pela China NMPA. \u00c9 indicado para melhorar o controlo da glicose no sangue em doentes adultos com diabetes tipo 2<\/p>","protected":false},"author":4,"featured_media":416,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[70],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/posts\/415"}],"collection":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/comments?post=415"}],"version-history":[{"count":0,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/posts\/415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/media\/416"}],"wp:attachment":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/media?parent=415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/categories?post=415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/tags?post=415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}